Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

by Lin Cai, Jian-Zhong Zhang, Xu Yao, Jun Gu, Quan-Zhong Liu, Min Zheng, Shi-Fa Zhang, Jin-Hua Xu, Cheng-Xin Li, Hao Cheng, Qing Guo, Wei-Li Pan, Shen-Qiu Li, Ruo-Yu Li, Zai-Pei Guo, Zhi-Qi Song, Shan-Shan Li, Xiu-Qin Dong, Linda Wang, Rong Fu, Pascaline Regnault, Pascal Charef, Rafal Mazur, Manmath Patekar, Jing Ni, Li-Shao Guo
Published 2020-11-01